In a filing, Corvus Pharmaceuticals Inc revealed its Director ORBIMED ADVISORS LLC unloaded Company’s shares for reported $4.89 million on Jun 27 ’25. In the deal valued at $4.16 per share,1,176,332 shares were sold. As a result of this transaction, ORBIMED ADVISORS LLC now holds 7,165,006 shares worth roughly $27.66 million.
Then, Thompson Peter A. sold 1,176,332 shares, generating $4,891,894 in total proceeds. Upon selling the shares at $4.16, the Director now owns 7,165,006 shares.
H.C. Wainwright initiated its Corvus Pharmaceuticals Inc [CRVS] rating to a Buy in a research note published on January 02, 2025; the price target was $11. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in mid August with a ‘”an Outperform”‘ rating. Cantor Fitzgerald started covering the stock on May 27, 2021. It rated CRVS as “an Overweight”.
Price Performance Review of CRVS
On Tuesday, Corvus Pharmaceuticals Inc [NASDAQ:CRVS] saw its stock fall -3.50% to $3.86. Over the last five days, the stock has lost -11.06%. Corvus Pharmaceuticals Inc shares have risen nearly 106.42% since the year began. Nevertheless, the stocks have fallen -27.85% over the past one year. While a 52-week high of $10.00 was reached on 01/06/25, a 52-week low of $1.75 was recorded on 04/09/25.
Levels Of Support And Resistance For CRVS Stock
The 24-hour chart illustrates a support level at 3.70, which if violated will result in even more drops to 3.54. On the upside, there is a resistance level at 4.03. A further resistance level may holdings at 4.20.
How much short interest is there in Corvus Pharmaceuticals Inc?
A steep rise in short interest was recorded in Corvus Pharmaceuticals Inc stocks on 2025-06-13, growing by 0.71 million shares to a total of 7.94 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 7.23 million shares. There was a rise of 8.91%, which implies that there is a positive sentiment for the stock.
